← Eichor
Condition: Advanced Triple Negative Breast Cancers Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Advanced Triple Negative Breast Cancers

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR220
EARLY_Phase 1 · 1 location(s) · Xiaorong Sun · NCT07340424Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
Phase 3 · 1 location(s) · Fudan University · NCT05806060Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unrese
Phase 1 · 4 location(s) · National Cancer Institute (NCI) · NCT05111561a Single-arm, Single-center, Open Clinical Study
Phase N/A · 1 location(s) · Beijing Geekgene Technology Co., LTD · NCT06431100A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Phase 2 · 13 location(s) · Processa Pharmaceuticals · NCT06568692A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 47 location(s) · Bristol-Myers Squibb · NCT04895709A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
Phase 1 · 2 location(s) · Hefei TG ImmunoPharma Co., Ltd. · NCT05746897A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
Phase 2 · 1 location(s) · Mabwell (Shanghai) Bioscience Co., Ltd. · NCT06492005A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Phase 1 · 10 location(s) · Dren Bio · NCT06999187Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC
Phase N/A · 1 location(s) · Fudan University · NCT07705438QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in
Phase 2 · 1 location(s) · Jiangsu Cancer Institute & Hospital · NCT07601178NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial
Phase 2 · 1 location(s) · The Netherlands Cancer Institute · NCT06342037Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (
EARLY_Phase 1 · 1 location(s) · University of Alabama at Birmingham · NCT04861077A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Phase 1/Phase 2 · 9 location(s) · Apollo Therapeutics Ltd · NCT06399757A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Phase 1 · 10 location(s) · Compass Therapeutics · NCT06150664A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Phase 1/Phase 2 · 14 location(s) · Volastra Therapeutics, Inc. · NCT05902988Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
Phase 1/Phase 2 · 1 location(s) · National University Hospital, Singapore · NCT05035745A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
Phase 1/Phase 2 · 1 location(s) · Shenzhen Majory Biotechnology Co., Ltd. · NCT07208149Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Andr
Phase 3 · 1 location(s) · Fudan University · NCT05954442Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone M
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT06538896Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07486089A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecul
Phase 1/Phase 2 · 8 location(s) · Marengo Therapeutics, Inc. · NCT06827613Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Phase 2 · 1 location(s) · Fudan University · NCT06649331TT-702 in Patients With Advanced Solid Tumours.
Phase 1/Phase 2 · 3 location(s) · Cancer Research UK · NCT05272709Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
Phase 1/Phase 2 · 1 location(s) · University of California, Irvine · NCT07064018A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who H
Phase 3 · 1 location(s) · Jiangsu Alphamab Biopharmaceuticals Co., Ltd · NCT07533123Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or M
Phase 3 · 1 location(s) · Fudan University · NCT05760378Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer
Phase 1/Phase 2 · 1 location(s) · Fujian Cancer Hospital · NCT05019690AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative
Phase 3 · 1 location(s) · Akeso · NCT06767527
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.